A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Public ClinicalTrials.gov record NCT00097981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Subjects With Newly Diagnosed Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Study identification
- NCT ID
- NCT00097981
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2004
- Primary completion
- Sep 30, 2007
- Completion
- Sep 30, 2009
- Last update posted
- Apr 6, 2017
2005 – 2009
United States locations
- U.S. sites
- 58
- U.S. states
- 25
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fountain Valley | California | — | — |
| Not listed | Greenbrae | California | — | — |
| Not listed | La Verne | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | New London | Connecticut | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orange City | Florida | — | — |
| Not listed | Ormond Beach | Florida | — | — |
| Not listed | Lawrenceville | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Saint Louis Park | Minnesota | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Englewood | New Jersey | — | — |
| Not listed | Hackensack | New Jersey | — | — |
| Not listed | Jersey City | New Jersey | — | — |
| Not listed | Voorhees Township | New Jersey | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Armonk | New York | — | — |
| Not listed | Box 302 | New York | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Nyack | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Valhalla | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Eugene | Oregon | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Wynnewood | Pennsylvania | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Easley | South Carolina | — | — |
| Not listed | Sumter | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Bedford | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Fredericksburg | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Vancouver | Washington | — | — |
| Not listed | Yakima | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00097981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2017 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00097981 live on ClinicalTrials.gov.